Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 9476Neoplasms 6587Prostatic Neoplasms 4399Colorectal Neoplasms 3977Lung Neoplasms 3642Carcinoma, Non-Small-Cell Lung 3583Pancreatic Neoplasms 2478Carcinoma, Hepatocellular 2411Leukemia, Myeloid, Acute 2265Multiple Myeloma 2120Stomach Neoplasms 2108Neoplasm Metastasis 1911Head and Neck Neoplasms 1869Ovarian Neoplasms 1773Precursor Cell Lymphoblastic Leukemia-Lymphoma 1734Lymphoma 1729Brain Neoplasms 1699Rectal Neoplasms 1676Melanoma 1654Colonic Neoplasms 1629Leukemia 1500Uterine Cervical Neoplasms 1499Recurrence 1485Esophageal Neoplasms 1311Glioblastoma 1307Lymphoma, Non-Hodgkin 1204Leukemia, Lymphocytic, Chronic, B-Cell 1120Squamous Cell Carcinoma of Head and Neck 1109Urinary Bladder Neoplasms 1078Lymphoma, Follicular 1067

Interventions

trifluridine tipiracil drug combination 1Trifluridine 1Taxes 1Ramucirumab 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Clinical Stage III Gastric Cancer AJCC v8 × Clear all
NCT04660760 2024-04-01

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

Academic and Community Cancer Research United

Phase 2 Unknown
116 enrolled
Gastrointestinal

Clinical Stage III Gastric Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡